摘要
目的探讨人类白细胞抗原(human leukocyte antigen,HLA)-DRB1等位基因多态性与阿德福韦酯(adefovir,ADV)抗病毒疗效相关性。方法以服用阿德福韦酯抗病毒治疗的山西地区家族性慢性乙型肝炎患者56例为研究对象,采用聚合酶链反应-序列特异性寡核苷酸探针技术(polymerase chain reaction sequence specific oligonucleotide probe,PCR-SSOP)结合荧光磁珠流式检测技术,进行HLA-DRB1等位基因的检测,分析比较治疗有效组与无效组HLA-DRB1各等位基因频率的差异。结果阿德福韦酯治疗有效组HLA-DRB1*04等位基因频率明显高于无效组(18.3%vs3.9%,χ2=5.699,P<0.05,OR=5.612);而有效组HLA-DRB1*07等位基因频率明显低于无效组(1.7%vs15.4%,χ2=5.359,P<0.05,OR=10.727),其他各等位基因频率在两组间差异无显著性。结论 HLA-DRB1*04可能是阿德福韦酯治疗有效的预测指标,而HLA-DRB1*07可能是阿德福韦酯治疗无效的预测指标。
Objective To explore the relations of human leukocyte antigen （HLA） -DRB1 polymorphism with antiviral effect of adefovir. Methods The familiar chronic hepatitis B patients in Shanxi province treated with adefovir were divided into effective group and ineffective group.HLA-DRB1 alleles were detected using polymerase chain reaction sequence specific oligonucleotide probe （PCR-SSOP） and flow PRATM beads.The frequencies of HLA-DRB1 were analyzed between two groups. Results The frequency of HLA-DRB1＊04 in effective group was significantly higher than in ineffective group（18.3% vs 3.9%,χ2=5.699,P0.05,OR=5.612）.The frequency of HLA-DRB1＊07 was significantly lower in effective group than in ineffective group（1.7% vs 15.4%,χ^2=5.359,P0.05,OR=10.727）.The frequencies of other DRB1 alleles were not significantly different between 2 groups（P0.05）. Conclusion HLA-DRB1＊ 04 may be an effective treatment predictor marker of adefovir,while HLA-DRB1 ＊ 07 may be an ineffective treatment predictor marker of adefovir.
出处
《山西医科大学学报》
CAS
2010年第5期411-413,共3页
Journal of Shanxi Medical University
基金
山西省高教科技研究自筹项目(20091173)
关键词
人类白细胞抗原
乙型肝炎
疗效
抗病毒治疗
human leukocyte antigen
hepatitis B
treatment outcome
antiviral therapy
